新诊断的同类重组缺陷的晚期卵巢癌的老年患者中PARP抑制剂的有效性和毒性:剂量调整的作用
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
在PubMed上查看摘要
概括
此摘要是机器生成的。在患有HRD的老年卵巢癌患者中,多 (腺二酸) 聚合酶抑制剂 (PARPi) 显著改善无进展生存期 (PFS). 年龄没有影响PARPi的疗效,老年患者在剂量调整后能耐受治疗.
科学领域
- 癌症学
- 遗传学
- 药理学
背景情况
- 卵巢癌是妇科癌症死亡的主要原因.
- 同源重组缺陷 (HRD) 和BRCA突变是治疗的关键目标.
- 多 (腺二酸) 聚合酶抑制剂 (PARPi) 已在卵巢癌中显示出有效性.
研究的目的
- 评估年龄对卵巢癌中PARPi维持疗法的影响.
- 评估不同年龄组的无进展生存期 (PFS).
- 分析与年龄相关的剂量调整,停用和不良事件.
主要方法
- 对324名患有BRCA突变或HRD的晚期卵巢癌患者的分析.
- 根据年龄分层的PARPi使用者与非使用者的PFS比较 (< 60岁与≥ 60岁).
- 对剂量调整,停用和不良事件的评估.
主要成果
- 在两个年龄组 (<60岁和≥60岁) 中,PARPi显著改善了PFS.
- 在年龄组之间没有发现PFS益处的显著差异 (HR=0. 95, p=0. 76).
- 在老年患者中,剂量调整更为频繁 (63. 9% vs 46. 5%).
结论
- 在患有HRD的老年卵巢癌患者中,PARPi疗法有效改善PFS.
- 在老年患者中,PARPi的毒性概况与年轻患者相似.
- 老年患者受益于剂量调整,这不会对PFS结果产生负面影响.
相关概念视频
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...